Leena Pradhan-Nabzdyk, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuropeptides | 5 | 2013 | 950 | 1.210 |
Why?
|
| RNA, Small Interfering | 14 | 2024 | 3424 | 1.210 |
Why?
|
| Wound Healing | 10 | 2016 | 2795 | 0.980 |
Why?
|
| Diabetic Neuropathies | 6 | 2016 | 407 | 0.880 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2016 | 1119 | 0.760 |
Why?
|
| Thrombospondins | 3 | 2024 | 197 | 0.650 |
Why?
|
| Substance P | 4 | 2015 | 331 | 0.620 |
Why?
|
| Endothelium, Vascular | 9 | 2012 | 4423 | 0.550 |
Why?
|
| Cocaine | 4 | 2008 | 944 | 0.550 |
Why?
|
| Neuropeptide Y | 3 | 2011 | 194 | 0.520 |
Why?
|
| Carotid Artery Injuries | 1 | 2016 | 96 | 0.510 |
Why?
|
| Vasoconstrictor Agents | 3 | 2008 | 653 | 0.450 |
Why?
|
| Aorta | 6 | 2016 | 2040 | 0.440 |
Why?
|
| Angioplasty, Balloon | 1 | 2016 | 591 | 0.400 |
Why?
|
| Tunica Intima | 1 | 2014 | 455 | 0.400 |
Why?
|
| Receptors, Neurokinin-1 | 2 | 2015 | 133 | 0.390 |
Why?
|
| Inflammation Mediators | 4 | 2014 | 1890 | 0.390 |
Why?
|
| Skin Ulcer | 1 | 2013 | 131 | 0.390 |
Why?
|
| Angioplasty | 1 | 2014 | 353 | 0.380 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2011 | 47 | 0.380 |
Why?
|
| Interleukin-8 | 2 | 2011 | 699 | 0.360 |
Why?
|
| Muscle, Smooth, Vascular | 7 | 2016 | 1494 | 0.340 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2024 | 701 | 0.330 |
Why?
|
| Endothelin-1 | 2 | 2008 | 295 | 0.330 |
Why?
|
| Gene Silencing | 6 | 2016 | 1504 | 0.320 |
Why?
|
| Aortic Aneurysm | 1 | 2014 | 649 | 0.320 |
Why?
|
| Cytokines | 4 | 2013 | 7426 | 0.310 |
Why?
|
| Transfection | 8 | 2024 | 5739 | 0.310 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 805 | 0.300 |
Why?
|
| Skin | 4 | 2016 | 4482 | 0.260 |
Why?
|
| Cocaine-Related Disorders | 2 | 2007 | 458 | 0.250 |
Why?
|
| Diabetic Foot | 3 | 2015 | 383 | 0.250 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 2188 | 0.240 |
Why?
|
| Heart Atria | 1 | 2011 | 1363 | 0.240 |
Why?
|
| Acetylcholine | 2 | 2005 | 628 | 0.230 |
Why?
|
| Ischemia | 1 | 2013 | 1904 | 0.230 |
Why?
|
| Hindlimb | 2 | 2005 | 512 | 0.230 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 1370 | 0.220 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 11906 | 0.220 |
Why?
|
| Hyperglycemia | 1 | 2011 | 1389 | 0.200 |
Why?
|
| Inflammation | 4 | 2015 | 10860 | 0.200 |
Why?
|
| Vasodilator Agents | 2 | 2005 | 988 | 0.200 |
Why?
|
| Gelatin | 1 | 2024 | 227 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 5889 | 0.190 |
Why?
|
| RNA Interference | 4 | 2014 | 2828 | 0.180 |
Why?
|
| Veins | 2 | 2017 | 769 | 0.180 |
Why?
|
| Arginine | 1 | 2024 | 931 | 0.180 |
Why?
|
| Vascular System Injuries | 1 | 2024 | 245 | 0.170 |
Why?
|
| Nitric Oxide | 2 | 2008 | 2142 | 0.170 |
Why?
|
| Vascular Resistance | 1 | 2003 | 939 | 0.170 |
Why?
|
| Endothelial Cells | 5 | 2024 | 3586 | 0.160 |
Why?
|
| Rabbits | 4 | 2015 | 4730 | 0.160 |
Why?
|
| Hyperplasia | 3 | 2024 | 1142 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2014 | 3418 | 0.150 |
Why?
|
| Polyethyleneimine | 2 | 2016 | 70 | 0.140 |
Why?
|
| Heparin | 1 | 2024 | 1635 | 0.140 |
Why?
|
| Animals | 24 | 2024 | 168800 | 0.130 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 2 | 2024 | 79 | 0.130 |
Why?
|
| Gene Expression | 2 | 2008 | 7582 | 0.130 |
Why?
|
| Macrophages | 3 | 2016 | 5776 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2016 | 636 | 0.130 |
Why?
|
| Cell Adhesion | 6 | 2014 | 3089 | 0.120 |
Why?
|
| Methacrylates | 1 | 2015 | 109 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2024 | 10433 | 0.120 |
Why?
|
| Nitroprusside | 2 | 2005 | 271 | 0.110 |
Why?
|
| Rats | 7 | 2024 | 23717 | 0.110 |
Why?
|
| Alginates | 1 | 2015 | 248 | 0.110 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 2210 | 0.110 |
Why?
|
| Growth Inhibitors | 1 | 2014 | 375 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2536 | 0.100 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 437 | 0.100 |
Why?
|
| Arteries | 1 | 2017 | 1121 | 0.100 |
Why?
|
| Growth Substances | 1 | 2014 | 758 | 0.100 |
Why?
|
| Cell-Matrix Junctions | 1 | 2011 | 21 | 0.100 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 314 | 0.100 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 608 | 0.090 |
Why?
|
| Genetic Techniques | 1 | 2014 | 429 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 750 | 0.090 |
Why?
|
| Alloxan | 1 | 2009 | 13 | 0.090 |
Why?
|
| Dermis | 1 | 2011 | 204 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2014 | 1205 | 0.080 |
Why?
|
| Cells, Cultured | 6 | 2011 | 18967 | 0.080 |
Why?
|
| Saphenous Vein | 2 | 2010 | 519 | 0.080 |
Why?
|
| Receptor, Endothelin A | 1 | 2008 | 55 | 0.080 |
Why?
|
| Mast Cells | 1 | 2016 | 1404 | 0.080 |
Why?
|
| Receptor, Endothelin B | 1 | 2008 | 46 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1996 | 0.080 |
Why?
|
| Ear | 1 | 2009 | 172 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 934 | 0.080 |
Why?
|
| U937 Cells | 1 | 2008 | 259 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2007 | 8113 | 0.070 |
Why?
|
| Collagen | 1 | 2016 | 2617 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1189 | 0.070 |
Why?
|
| Heart Failure | 1 | 2011 | 11837 | 0.070 |
Why?
|
| Microvessels | 1 | 2011 | 590 | 0.070 |
Why?
|
| Stem Cells | 2 | 2013 | 3537 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2014 | 7850 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2013 | 4133 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2013 | 2927 | 0.060 |
Why?
|
| Ephedrine | 1 | 2005 | 50 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2024 | 1602 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 707 | 0.060 |
Why?
|
| Bradykinin | 1 | 2005 | 205 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 938 | 0.060 |
Why?
|
| Regional Blood Flow | 2 | 2005 | 1479 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 10737 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1592 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2014 | 3635 | 0.060 |
Why?
|
| Dogs | 2 | 2024 | 3824 | 0.060 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2024 | 43 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2008 | 1133 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2014 | 1456 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 4565 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 3501 | 0.060 |
Why?
|
| Pipecolic Acids | 1 | 2024 | 77 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2012 | 5881 | 0.060 |
Why?
|
| Norepinephrine | 2 | 2005 | 898 | 0.060 |
Why?
|
| Penis | 1 | 2005 | 209 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2009 | 798 | 0.060 |
Why?
|
| Superoxides | 1 | 2005 | 382 | 0.060 |
Why?
|
| Computational Biology | 1 | 2016 | 3565 | 0.050 |
Why?
|
| Tyramine | 1 | 2003 | 55 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2024 | 330 | 0.050 |
Why?
|
| Oxygen | 1 | 2015 | 4247 | 0.050 |
Why?
|
| Hirudins | 1 | 2024 | 179 | 0.050 |
Why?
|
| Coronary Vessels | 2 | 2012 | 3094 | 0.050 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 56 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 3436 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 123 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2005 | 593 | 0.050 |
Why?
|
| Humans | 24 | 2024 | 766117 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2879 | 0.050 |
Why?
|
| Antithrombins | 1 | 2024 | 295 | 0.050 |
Why?
|
| Time Factors | 4 | 2013 | 40108 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3445 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2009 | 18321 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2024 | 373 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2005 | 606 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 1376 | 0.040 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2005 | 504 | 0.040 |
Why?
|
| Leukocytes | 1 | 2008 | 2030 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2014 | 12775 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2003 | 844 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2009 | 3227 | 0.040 |
Why?
|
| Mice | 6 | 2016 | 81839 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2005 | 8532 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2024 | 23605 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 8038 | 0.040 |
Why?
|
| Cell Count | 2 | 2012 | 1825 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 2016 | 1242 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 1852 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 1167 | 0.030 |
Why?
|
| Antioxidants | 1 | 2004 | 1671 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 145 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 149 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 1899 | 0.030 |
Why?
|
| GATA4 Transcription Factor | 1 | 2016 | 125 | 0.030 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2005 | 1663 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 12130 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2004 | 2573 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 6493 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2024 | 1980 | 0.030 |
Why?
|
| Porosity | 1 | 2015 | 347 | 0.030 |
Why?
|
| Gels | 1 | 2015 | 420 | 0.030 |
Why?
|
| Polyethylene Terephthalates | 1 | 2014 | 112 | 0.030 |
Why?
|
| Adsorption | 1 | 2014 | 198 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 651 | 0.030 |
Why?
|
| Bandages | 1 | 2015 | 270 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 441 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 372 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2004 | 3140 | 0.030 |
Why?
|
| Tissue Engineering | 2 | 2015 | 1857 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 97 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2024 | 5126 | 0.020 |
Why?
|
| Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2010 | 5 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2015 | 1886 | 0.020 |
Why?
|
| Air Pressure | 1 | 2010 | 75 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2015 | 701 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2476 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2011 | 456 | 0.020 |
Why?
|
| Male | 9 | 2024 | 363935 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 590 | 0.020 |
Why?
|
| Fluorescence | 1 | 2012 | 751 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 286 | 0.020 |
Why?
|
| Quality Control | 1 | 2012 | 835 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 462 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2024 | 4857 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 9527 | 0.020 |
Why?
|
| Cell Movement | 2 | 2011 | 5196 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 959 | 0.020 |
Why?
|
| Aged | 4 | 2016 | 171219 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 314 | 0.020 |
Why?
|
| Endothelins | 1 | 2007 | 127 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 1685 | 0.020 |
Why?
|
| Reactive Oxygen Species | 2 | 2005 | 2144 | 0.020 |
Why?
|
| Middle Aged | 4 | 2016 | 223083 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2004 | 11642 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 22341 | 0.020 |
Why?
|
| Reserpine | 1 | 2005 | 63 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1676 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 2005 | 155 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5747 | 0.020 |
Why?
|
| Streptozocin | 1 | 2005 | 189 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2005 | 291 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 9521 | 0.010 |
Why?
|
| Catecholamines | 1 | 2005 | 388 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3801 | 0.010 |
Why?
|
| Amphetamine | 1 | 2005 | 222 | 0.010 |
Why?
|
| Indinavir | 1 | 2004 | 73 | 0.010 |
Why?
|
| Nelfinavir | 1 | 2004 | 68 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2007 | 911 | 0.010 |
Why?
|
| Peroxidase | 1 | 2007 | 610 | 0.010 |
Why?
|
| Cattle | 1 | 2009 | 3801 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 1928 | 0.010 |
Why?
|
| Alkynes | 1 | 2004 | 326 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2004 | 262 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2004 | 436 | 0.010 |
Why?
|
| Benzoxazines | 1 | 2004 | 320 | 0.010 |
Why?
|
| Zidovudine | 1 | 2004 | 626 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 1527 | 0.010 |
Why?
|
| Oxazines | 1 | 2004 | 358 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2017 | 3787 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 589 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 597 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 1092 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9599 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2005 | 1736 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 5020 | 0.010 |
Why?
|
| Boston | 1 | 2012 | 9335 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 1967 | 0.010 |
Why?
|
| Female | 4 | 2024 | 396233 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 1610 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 1938 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 22228 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20137 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11035 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13616 | 0.010 |
Why?
|
| Anesthesia | 1 | 2005 | 1595 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 21513 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4342 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 39243 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 16716 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 41684 | 0.010 |
Why?
|
| Adult | 2 | 2013 | 223139 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2012 | 54812 | 0.000 |
Why?
|
| Brain | 1 | 2004 | 27177 | 0.000 |
Why?
|